| MYCN-Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc-/Glutathione Axis KV Floros, JY Cai, S Jacob, R Kurupi, CK Fairchild, M Shende, CM Coon, ... Cancer research 81 (7), 1896-1908, 2021 | 96 | 2021 |
| Increased Synthesis of MCL-1 Protein Underlies Initial Survival of EGFR-Mutant Lung Cancer to EGFR Inhibitors and Provides a Novel Drug Target KA Song, Y Hosono, C Turner, S Jacob, TL Lochmann, Y Murakami, ... Clinical Cancer Research 24 (22), 5658-5672, 2018 | 59 | 2018 |
| Long circulating PEGylated PLGA nanoparticles of cytarabine for targeting leukemia KS Yadav, S Jacob, G Sachdeva, K Chuttani, AK Mishra, KK Sawant Journal of microencapsulation 28 (8), 729-742, 2011 | 44 | 2011 |
| Androgen receptor as a regulator of ZEB2 expression and its implications in epithelial-to-mesenchymal transition in prostate cancer S Jacob, S Nayak, G Fernandes, RS Barai, S Menon, UK Chaudhari, ... Endocr Relat Cancer 21 (3), 473-486, 2014 | 41 | 2014 |
| The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity DAR Heisey, TL Lochmann, KV Floros, CM Coon, KM Powell, S Jacob, ... Clinical Cancer Research 25 (5), 1664-1675, 2019 | 36 | 2019 |
| Intracellular delivery of etoposide loaded biodegradable nanoparticles: cytotoxicity and cellular uptake studies KS Yadav, S Jacob, G Sachdeva, KK Sawant Journal of Nanoscience and Nanotechnology 11 (8), 6657-6667, 2011 | 28 | 2011 |
| High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition J Cai, S Jacob, R Kurupi, KM Dalton, C Coon, P Greninger, RK Egan, ... Cell reports 40 (4), 2022 | 17 | 2022 |
| Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma KM Dalton, K Krytska, TL Lochmann, R Sano, C Casey, A D'Aulerio, ... Molecular cancer therapeutics 20 (8), 1400-1411, 2021 | 14 | 2021 |
| A triad of telomerase, androgen receptor and early growth response 1 in prostate cancer cells S Jacob, S Nayak, R Kakar, UK Chaudhari, D Joshi, BR Vundinti, ... Cancer Biology & Therapy 17 (4), 439-448, 2016 | 14 | 2016 |
| Differential expression of calreticulin, a reticuloplasmin in primate endometrium T Parmar, S Nimbkar-Joshi, RR Katkam, S Gadkar-Sable, U Chaudhari, ... Human reproduction 24 (9), 2205-2216, 2009 | 14 | 2009 |
| Endometrial epithelial cell modifications in response to embryonic signals in bonnet monkeys (Macaca radiata) S Nimbkar-Joshi, RR Katkam, UK Chaudhari, S Jacob, DD Manjramkar, ... Histochemistry and cell biology 138 (2), 289-304, 2012 | 13 | 2012 |
| Pharmaceutical interference of the EWS-FLI1–driven transcriptome by cotargeting H3K27ac and RNA polymerase activity in Ewing sarcoma DAR Heisey, S Jacob, TL Lochmann, R Kurupi, MS Ghotra, ML Calbert, ... Molecular Cancer Therapeutics 20 (10), 1868-1879, 2021 | 12 | 2021 |
| Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors KV Floros, S Jacob, R Kurupi, CK Fairchild, B Hu, M Puchalapalli, ... Cell Death & Disease 12 (2), 179, 2021 | 12 | 2021 |
| Unmasking Bcl-2 addiction in synovial sarcoma by overcoming low Noxa CK Fairchild Jr, KV Floros, S Jacob, CM Coon, M Puchalapalli, B Hu, ... Cancers 13 (10), 2310, 2021 | 7 | 2021 |
| Pharmacologic inhibition of SHP2 blocks both PI3K and MEK signaling in low-epiregulin HNSCC via GAB1 R Kurupi, KV Floros, S Jacob, AT Chawla, J Cai, B Hu, M Puchalapalli, ... Cancer research communications 2 (9), 1061-1074, 2022 | 4 | 2022 |
| Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma. CK Fairchild, K Floros, S Jacob, C Coon, M Puchalapalli, B Hu, ... Journal of Clinical Oncology 38 (15_suppl), e23561-e23561, 2020 | 4 | 2020 |
| Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models S Jacob, TH Turner, J Cai, KV Floros, AK Yu, CM Coon, R Khatri, ... PNAS nexus 1 (5), pgac232, 2022 | 2 | 2022 |
| Nanomaterials physics: A critical review KS Yadav, S Jacob, AM Pethe Photophysics and Nanophysics in Therapeutics, 207-216, 2022 | 2 | 2022 |
| R9: A novel NuRD complex inhibitor for targeted therapy in triple negative breast cancer (TNBC) K Zhang, S Jacob, M Dozmorov, I Babic, E Nurmemmedov, AC Faber Cancer Research 84 (6_Supplement), 5976-5976, 2024 | | 2024 |
| Epithelial-mesenchymal transition and resistance to EGFR inhibitors S Jacob, R Kurupi, AC Faber Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC, 105-124, 2023 | | 2023 |
Sosipatros Alexander BoikosHematology Oncology Fellow, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Hospital在 jhmi.edu 的电子邮件经过验证
